Fanconi Anaemia is an inherited disorder which can lead to bone marrow failure, acute myeloid leukaemia and cancer. Fanconi Anaemia is a DNA repair disorder caused by the inability for the DNA to repair certain defects. A defect in any one of 22 different proteins may be involved in Fanconi Anaemia. The goal of this study is to identify drugs that can compensate for an absence or defect of one of the 22 Fanconi Anaemia proteins to re-enable functional DNA repair.
This team (Genome Stability Unit at St Vincent’s Institute) is already the first in the world to isolate and correctly assemble the Fanconi Anaemia proteins in a test tube.
The proposed study intends to leverage this tool to screen a library of >55,000 drug and drug-like compounds for the potential to enable normal DNA repair. This will be a first potential step towards development of new therapeutics to delay progression of Fanconi Anaemia.
2023-2025 (Fiona Riewoldt Nursing/Allied Health Fellowship): Utility of a neurobehavioural assessment for treatment planning, educational, and family support for children undergoing bone marrow transplant for non-malignant ...
Read more2022-2024 (Fiona Riewoldt Nursing/Allied Health Fellowship): Improving capability and capacity of nurses to assess and manage young people with symptoms associated with acquired and inherited bone marrow failure syndromes. Rachel Edwards, ...
Read more2016 – 2019 (Grant-in-Aid) Identification of microRNA biomarkers predictive of clinical outcomes in Aplastic Anaemia and Myelodysplastic Syndrome, Dr Lynette Chee, Melbourne Health. DNA is the genetic material which provides the information that ...
Read more2018-2020 (Grant in aid): Influences of clonal haematopoiesis in allogeneic bone marrow transplantation. Dr Paul Yeh and Professor Mark Dawson, The University of Melbourne. Dr Paul Yeh’s research focusses on using genetic testing to study clonal ...
Read more